Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor

3′- O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2′-deoxyuridine ( 1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nuclear medicine and biology 2005-08, Vol.32 (6), p.641-645
Hauptverfasser: Moharram, Sameh, Zhou, Aihua, Kumar, Piyush, Knaus, Edward E., Wiebe, Leonard I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 645
container_issue 6
container_start_page 641
container_title Nuclear medicine and biology
container_volume 32
creator Moharram, Sameh
Zhou, Aihua
Kumar, Piyush
Knaus, Edward E.
Wiebe, Leonard I.
description 3′- O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2′-deoxyuridine ( 1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radiochemical yield. The specific activity of [ 125I] 1 was 31.8 μCi/μg (680 MBq/μM). Protein binding, deiodination, cellular uptake and incorporation of 1 into cellular nucleic acids were measured by standard methods, and its in vivo biodistribution was determined in Balb/c mice bearing implanted EMT-6 tumors following intravenous injection. [ 125I] 1 degraded rapidly during the in vitro tests, thus impeding unequivocal assessment but indicating that it was only weakly protein bound and that it was resistant to deiodination under test conditions. Uptake of [ 125I] 1 by murine tumor cells (KBALB and KBALB-STK) in vitro was low (∼17 fmol/μg protein over 2 h) with only ∼0.3% (0.04–0.06 fmol/μg protein) of total uptake present in the DNA fraction. In the murine tumor model, liver, kidney, intestine and tumor showed the greatest uptake, with liver, intestine and blood all containing >5 injected dose per gram of tissue (%ID/g) during the 15-min to 2-h postinjection period. Maximum tissue/blood level ratios were 3.6 (2 h) for tumor and 6.4 (24 h) for liver. Low uptake in thyroid and stomach was indicative of minimal in vivo deiodination. [ 125I] 1 undergoes only minimal deoiodination under both in vitro and in vivo conditions. Under conditions of the in vitro NO release assay, 1 reacts to produce a single, major, unstable adduct that decomposes upon workup. Protein binding of [ 125I] 1 could not be assessed because of similar chemical reaction with albumin. Incorporation of radioactivity into the cellular nucleic acid fraction was low, and in vivo distribution of [ 125I] 1 was consistent with nonspecific reactivity towards tissue nucleophiles. The chemical reactivity of [ 125I] 1 mitigates against its use as a NO donor and as a tracer for this class of compounds.
doi_str_mv 10.1016/j.nucmedbio.2005.04.011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68056344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0969805105001058</els_id><sourcerecordid>68056344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-652eacdbe932d7d50ea1103c8a3364afca8bc83e05321687d01ad5fa68ff7d3d3</originalsourceid><addsrcrecordid>eNqFkcGKFDEQhoMo7uzqK2hOorBpk053uvu4LLouLCyInkRCOqlgxp5kTDrDtCefyYMP5JOYYQY9egqk_r_-qvoQes5oxSgTr9eVz3oDZnShqiltK9pUlLEHaMX6riaDYM1DtKKDGEhPW3aGzlNa0-JsGH2MzpigtegYW6Ff75VxIS1-_gLJpUvsPN65OQasYZrypCLO21l9Bay8ORZ3AZdY49Ic3ZhnFzwOFvPfP34SfE9ecjKC_w4eUp5s8Mtkcwx75UlDlukVacknzOr29nNpEUh9cBkI-yVHZ5yHS6xwWW2CkJwBMqoEBvsykNM47MsXNsGH-AQ9smpK8PT0XqCPb998uH5H7u5vbq-v7ojmYpiJaGtQ2oww8Np0pqWgGKNc94pz0SirVT_qngNtec1E3xnKlGmtEr21neGGX6AXx77bGL5lSLPcuHS4jPIQcpKiXFfwpinC7ijUMaQUwcptdBsVF8moPCCTa_kXmTwgk7SRBVlxPjtF5LGU__lOjIrg6iiAsujOQZRJO_AajIugZ2mC-2_IH0AesTE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68056344</pqid></control><display><type>article</type><title>Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Moharram, Sameh ; Zhou, Aihua ; Kumar, Piyush ; Knaus, Edward E. ; Wiebe, Leonard I.</creator><creatorcontrib>Moharram, Sameh ; Zhou, Aihua ; Kumar, Piyush ; Knaus, Edward E. ; Wiebe, Leonard I.</creatorcontrib><description>3′- O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2′-deoxyuridine ( 1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radiochemical yield. The specific activity of [ 125I] 1 was 31.8 μCi/μg (680 MBq/μM). Protein binding, deiodination, cellular uptake and incorporation of 1 into cellular nucleic acids were measured by standard methods, and its in vivo biodistribution was determined in Balb/c mice bearing implanted EMT-6 tumors following intravenous injection. [ 125I] 1 degraded rapidly during the in vitro tests, thus impeding unequivocal assessment but indicating that it was only weakly protein bound and that it was resistant to deiodination under test conditions. Uptake of [ 125I] 1 by murine tumor cells (KBALB and KBALB-STK) in vitro was low (∼17 fmol/μg protein over 2 h) with only ∼0.3% (0.04–0.06 fmol/μg protein) of total uptake present in the DNA fraction. In the murine tumor model, liver, kidney, intestine and tumor showed the greatest uptake, with liver, intestine and blood all containing &gt;5 injected dose per gram of tissue (%ID/g) during the 15-min to 2-h postinjection period. Maximum tissue/blood level ratios were 3.6 (2 h) for tumor and 6.4 (24 h) for liver. Low uptake in thyroid and stomach was indicative of minimal in vivo deiodination. [ 125I] 1 undergoes only minimal deoiodination under both in vitro and in vivo conditions. Under conditions of the in vitro NO release assay, 1 reacts to produce a single, major, unstable adduct that decomposes upon workup. Protein binding of [ 125I] 1 could not be assessed because of similar chemical reaction with albumin. Incorporation of radioactivity into the cellular nucleic acid fraction was low, and in vivo distribution of [ 125I] 1 was consistent with nonspecific reactivity towards tissue nucleophiles. The chemical reactivity of [ 125I] 1 mitigates against its use as a NO donor and as a tracer for this class of compounds.</description><identifier>ISSN: 0969-8051</identifier><identifier>EISSN: 1872-9614</identifier><identifier>DOI: 10.1016/j.nucmedbio.2005.04.011</identifier><identifier>PMID: 16026711</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Benzenesulfonylfuroxanyl NO donor ; Idoxuridine - analogs &amp; derivatives ; Idoxuridine - chemical synthesis ; Idoxuridine - pharmacokinetics ; Iodine Radioisotopes ; Iododeoxyuridine ; Isotope Labeling ; IUDR ; Male ; Mice ; Mice, Inbred BALB C ; Nitric Oxide Donors - chemical synthesis ; Nitric Oxide Donors - pharmacokinetics ; Nucleic acid fraction ; Oxadiazoles - chemical synthesis ; Oxadiazoles - pharmacokinetics ; Positron-Emission Tomography ; Radioimmunodetection ; Sarcoma, Experimental - diagnostic imaging ; Sarcoma, Experimental - metabolism ; Tumor Cells, Cultured ; Tumor uptake</subject><ispartof>Nuclear medicine and biology, 2005-08, Vol.32 (6), p.641-645</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-652eacdbe932d7d50ea1103c8a3364afca8bc83e05321687d01ad5fa68ff7d3d3</citedby><cites>FETCH-LOGICAL-c369t-652eacdbe932d7d50ea1103c8a3364afca8bc83e05321687d01ad5fa68ff7d3d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.nucmedbio.2005.04.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16026711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moharram, Sameh</creatorcontrib><creatorcontrib>Zhou, Aihua</creatorcontrib><creatorcontrib>Kumar, Piyush</creatorcontrib><creatorcontrib>Knaus, Edward E.</creatorcontrib><creatorcontrib>Wiebe, Leonard I.</creatorcontrib><title>Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor</title><title>Nuclear medicine and biology</title><addtitle>Nucl Med Biol</addtitle><description>3′- O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2′-deoxyuridine ( 1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radiochemical yield. The specific activity of [ 125I] 1 was 31.8 μCi/μg (680 MBq/μM). Protein binding, deiodination, cellular uptake and incorporation of 1 into cellular nucleic acids were measured by standard methods, and its in vivo biodistribution was determined in Balb/c mice bearing implanted EMT-6 tumors following intravenous injection. [ 125I] 1 degraded rapidly during the in vitro tests, thus impeding unequivocal assessment but indicating that it was only weakly protein bound and that it was resistant to deiodination under test conditions. Uptake of [ 125I] 1 by murine tumor cells (KBALB and KBALB-STK) in vitro was low (∼17 fmol/μg protein over 2 h) with only ∼0.3% (0.04–0.06 fmol/μg protein) of total uptake present in the DNA fraction. In the murine tumor model, liver, kidney, intestine and tumor showed the greatest uptake, with liver, intestine and blood all containing &gt;5 injected dose per gram of tissue (%ID/g) during the 15-min to 2-h postinjection period. Maximum tissue/blood level ratios were 3.6 (2 h) for tumor and 6.4 (24 h) for liver. Low uptake in thyroid and stomach was indicative of minimal in vivo deiodination. [ 125I] 1 undergoes only minimal deoiodination under both in vitro and in vivo conditions. Under conditions of the in vitro NO release assay, 1 reacts to produce a single, major, unstable adduct that decomposes upon workup. Protein binding of [ 125I] 1 could not be assessed because of similar chemical reaction with albumin. Incorporation of radioactivity into the cellular nucleic acid fraction was low, and in vivo distribution of [ 125I] 1 was consistent with nonspecific reactivity towards tissue nucleophiles. The chemical reactivity of [ 125I] 1 mitigates against its use as a NO donor and as a tracer for this class of compounds.</description><subject>Animals</subject><subject>Benzenesulfonylfuroxanyl NO donor</subject><subject>Idoxuridine - analogs &amp; derivatives</subject><subject>Idoxuridine - chemical synthesis</subject><subject>Idoxuridine - pharmacokinetics</subject><subject>Iodine Radioisotopes</subject><subject>Iododeoxyuridine</subject><subject>Isotope Labeling</subject><subject>IUDR</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nitric Oxide Donors - chemical synthesis</subject><subject>Nitric Oxide Donors - pharmacokinetics</subject><subject>Nucleic acid fraction</subject><subject>Oxadiazoles - chemical synthesis</subject><subject>Oxadiazoles - pharmacokinetics</subject><subject>Positron-Emission Tomography</subject><subject>Radioimmunodetection</subject><subject>Sarcoma, Experimental - diagnostic imaging</subject><subject>Sarcoma, Experimental - metabolism</subject><subject>Tumor Cells, Cultured</subject><subject>Tumor uptake</subject><issn>0969-8051</issn><issn>1872-9614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcGKFDEQhoMo7uzqK2hOorBpk053uvu4LLouLCyInkRCOqlgxp5kTDrDtCefyYMP5JOYYQY9egqk_r_-qvoQes5oxSgTr9eVz3oDZnShqiltK9pUlLEHaMX6riaDYM1DtKKDGEhPW3aGzlNa0-JsGH2MzpigtegYW6Ff75VxIS1-_gLJpUvsPN65OQasYZrypCLO21l9Bay8ORZ3AZdY49Ic3ZhnFzwOFvPfP34SfE9ecjKC_w4eUp5s8Mtkcwx75UlDlukVacknzOr29nNpEUh9cBkI-yVHZ5yHS6xwWW2CkJwBMqoEBvsykNM47MsXNsGH-AQ9smpK8PT0XqCPb998uH5H7u5vbq-v7ojmYpiJaGtQ2oww8Np0pqWgGKNc94pz0SirVT_qngNtec1E3xnKlGmtEr21neGGX6AXx77bGL5lSLPcuHS4jPIQcpKiXFfwpinC7ijUMaQUwcptdBsVF8moPCCTa_kXmTwgk7SRBVlxPjtF5LGU__lOjIrg6iiAsujOQZRJO_AajIugZ2mC-2_IH0AesTE</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Moharram, Sameh</creator><creator>Zhou, Aihua</creator><creator>Kumar, Piyush</creator><creator>Knaus, Edward E.</creator><creator>Wiebe, Leonard I.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor</title><author>Moharram, Sameh ; Zhou, Aihua ; Kumar, Piyush ; Knaus, Edward E. ; Wiebe, Leonard I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-652eacdbe932d7d50ea1103c8a3364afca8bc83e05321687d01ad5fa68ff7d3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Benzenesulfonylfuroxanyl NO donor</topic><topic>Idoxuridine - analogs &amp; derivatives</topic><topic>Idoxuridine - chemical synthesis</topic><topic>Idoxuridine - pharmacokinetics</topic><topic>Iodine Radioisotopes</topic><topic>Iododeoxyuridine</topic><topic>Isotope Labeling</topic><topic>IUDR</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nitric Oxide Donors - chemical synthesis</topic><topic>Nitric Oxide Donors - pharmacokinetics</topic><topic>Nucleic acid fraction</topic><topic>Oxadiazoles - chemical synthesis</topic><topic>Oxadiazoles - pharmacokinetics</topic><topic>Positron-Emission Tomography</topic><topic>Radioimmunodetection</topic><topic>Sarcoma, Experimental - diagnostic imaging</topic><topic>Sarcoma, Experimental - metabolism</topic><topic>Tumor Cells, Cultured</topic><topic>Tumor uptake</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moharram, Sameh</creatorcontrib><creatorcontrib>Zhou, Aihua</creatorcontrib><creatorcontrib>Kumar, Piyush</creatorcontrib><creatorcontrib>Knaus, Edward E.</creatorcontrib><creatorcontrib>Wiebe, Leonard I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moharram, Sameh</au><au>Zhou, Aihua</au><au>Kumar, Piyush</au><au>Knaus, Edward E.</au><au>Wiebe, Leonard I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor</atitle><jtitle>Nuclear medicine and biology</jtitle><addtitle>Nucl Med Biol</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>32</volume><issue>6</issue><spage>641</spage><epage>645</epage><pages>641-645</pages><issn>0969-8051</issn><eissn>1872-9614</eissn><abstract>3′- O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2′-deoxyuridine ( 1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radiochemical yield. The specific activity of [ 125I] 1 was 31.8 μCi/μg (680 MBq/μM). Protein binding, deiodination, cellular uptake and incorporation of 1 into cellular nucleic acids were measured by standard methods, and its in vivo biodistribution was determined in Balb/c mice bearing implanted EMT-6 tumors following intravenous injection. [ 125I] 1 degraded rapidly during the in vitro tests, thus impeding unequivocal assessment but indicating that it was only weakly protein bound and that it was resistant to deiodination under test conditions. Uptake of [ 125I] 1 by murine tumor cells (KBALB and KBALB-STK) in vitro was low (∼17 fmol/μg protein over 2 h) with only ∼0.3% (0.04–0.06 fmol/μg protein) of total uptake present in the DNA fraction. In the murine tumor model, liver, kidney, intestine and tumor showed the greatest uptake, with liver, intestine and blood all containing &gt;5 injected dose per gram of tissue (%ID/g) during the 15-min to 2-h postinjection period. Maximum tissue/blood level ratios were 3.6 (2 h) for tumor and 6.4 (24 h) for liver. Low uptake in thyroid and stomach was indicative of minimal in vivo deiodination. [ 125I] 1 undergoes only minimal deoiodination under both in vitro and in vivo conditions. Under conditions of the in vitro NO release assay, 1 reacts to produce a single, major, unstable adduct that decomposes upon workup. Protein binding of [ 125I] 1 could not be assessed because of similar chemical reaction with albumin. Incorporation of radioactivity into the cellular nucleic acid fraction was low, and in vivo distribution of [ 125I] 1 was consistent with nonspecific reactivity towards tissue nucleophiles. The chemical reactivity of [ 125I] 1 mitigates against its use as a NO donor and as a tracer for this class of compounds.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16026711</pmid><doi>10.1016/j.nucmedbio.2005.04.011</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0969-8051
ispartof Nuclear medicine and biology, 2005-08, Vol.32 (6), p.641-645
issn 0969-8051
1872-9614
language eng
recordid cdi_proquest_miscellaneous_68056344
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Benzenesulfonylfuroxanyl NO donor
Idoxuridine - analogs & derivatives
Idoxuridine - chemical synthesis
Idoxuridine - pharmacokinetics
Iodine Radioisotopes
Iododeoxyuridine
Isotope Labeling
IUDR
Male
Mice
Mice, Inbred BALB C
Nitric Oxide Donors - chemical synthesis
Nitric Oxide Donors - pharmacokinetics
Nucleic acid fraction
Oxadiazoles - chemical synthesis
Oxadiazoles - pharmacokinetics
Positron-Emission Tomography
Radioimmunodetection
Sarcoma, Experimental - diagnostic imaging
Sarcoma, Experimental - metabolism
Tumor Cells, Cultured
Tumor uptake
title Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3′- O-(3-benzenesulfonylfuroxan-4-yl)-5-[ 125I]iodo-2′-deoxyuridine, a nucleoside-based nitric oxide donor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A10%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiosynthesis,%20in%20vitro%20cellular%20uptake%20and%20in%20vivo%20biodistribution%20of%203%E2%80%B2-%20O-(3-benzenesulfonylfuroxan-4-yl)-5-%5B%20125I%5Diodo-2%E2%80%B2-deoxyuridine,%20a%20nucleoside-based%20nitric%20oxide%20donor&rft.jtitle=Nuclear%20medicine%20and%20biology&rft.au=Moharram,%20Sameh&rft.date=2005-08-01&rft.volume=32&rft.issue=6&rft.spage=641&rft.epage=645&rft.pages=641-645&rft.issn=0969-8051&rft.eissn=1872-9614&rft_id=info:doi/10.1016/j.nucmedbio.2005.04.011&rft_dat=%3Cproquest_cross%3E68056344%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68056344&rft_id=info:pmid/16026711&rft_els_id=S0969805105001058&rfr_iscdi=true